SCTX
HOLD / NEUTRALNeutralComposite
36.30
Technical
31.40
Fundamental
39.60
Rank
—
Price
18.02
Hurst
—
As of
Jul 29, 2026
Daily
Scribe Therapeutics Inc.
HealthcareBiotechnologyScribe Therapeutics is a clinical-stage biotech firm developing genetic treatments using CRISPR technology to treat cardiometabolic diseases. The company's pipeline includes three main programs: STX-1150, an epigenetic silencing therapy targeting the PCSK9 gene; STX-1200, a gene-editing approach for elevated Lp(a) levels; and STX-1400, designed to reduce APOC3 gene expression. The company employs proprietary CRISPR platforms that enable either temporary gene silencing without DNA modification or precise permanent gene editing.
Market cap
$608.5M
P/E (trailing)
—
P/E (forward)
-8.89
PEG ratio
—
Dividend yield
—
Beta
—
52w range
17.31 – 39.60
Return on equity
—
Profit margin
-97.00%
Revenue growth
-60.80%
Earnings growth
—
Price history
1Y: 29.10 (+53.4%) · range 18.06–37.25
Cycle position
71/ 100 cycle scoreAPPROACHING EXIT
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 0 · NOT READY · exit proximity 15
Conviction
12/ 100 · maturity 0%
Buildup.335
EMA entry setup.420
Fundamentals.2540
Volume profile
POC
30.02
Price vs POC
-3.0%
Overhead supply
50%
Runway
+0.1%
Value area 23.11–38.71 · 50% of 37d volume overhead · moderate overhead
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +29.83% | +56.51% | mature |
| 40d | +24.96% | +56.51% | 26/40d |